←Back to Expert Scholars
Translational Medicine / 转化医学Allogeneic HCT, Conditioning and AML
Edward Copelan
MD
🏢Atrium Health Levine Cancer Institute🌐USA
Chair, Department of Hematologic Oncology and Blood Disorders
65
h-index
0
Key Papers
0
Key Contributions
👥Biography 个人简介
Edward Copelan has shaped allogeneic HCT practice through studies of busulfan-based conditioning and AML transplant timing. His CIBMTR analyses inform regimen selection. He chairs hematologic oncology at Levine Cancer Institute.
Share:
🧪Research Fields 研究领域
busulfan
fludarabine
AML transplant
allogeneic HCT
conditioning regimens
🎓Key Contributions 主要贡献
Representative Works 代表性著作
📄Data Sources 数据来源
Last updated: 2026-04-01 | All information from publicly available academic sources
Related Experts 相关专家
Antoni Ribas
UCLA Jonsson Comprehensive Cancer Center
Melanoma ImmunotherapyCheckpoint Inhibitors
Drew M. Pardoll
Johns Hopkins University
Cancer ImmunologyPD-1/PD-L1 Pathway
Padmanee Sharma
MD Anderson Cancer Center
Bladder Cancer ImmunotherapyImmune Profiling
Naiyer A. Rizvi
Columbia University Irving Medical Center
Lung Cancer ImmunotherapyTumor Mutational Burden
关注 Edward Copelan 的研究动态
Follow Edward Copelan's research updates
留下邮箱，当我们发布与 Edward Copelan（Atrium Health Levine Cancer Institute）相关的新研究或访谈时，我们会通知你。
Explore More Experts
Discover the researchers shaping the future of cancer treatment